As an example, it is referred to the evaluation of novel albumin-binding radioligands by Kelly et al. [20] and Deberle et al. [21] who tested [177Lu]Lu-RPS-072, injected at 13–23 pmol in male LNCaP tumor-bearing mice and [177Lu]Lu-Ibu-DAB-PSMA, applied at 1.0 nmol in female PC-3 PIP tumor-bearing mice, respectively. The gene discussed is FOLH1; the disease is neoplasm.